Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand

Describes the burden of hepatitis C virus (HCV) infection. Estimates the impact of increased treatment uptake and efficacy on the projected health burden from liver-related complications in New Zealanders with chronic HCV infection. Also estimates the impact of delaying any access to new therapies f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	New Zealand medical journal 2014-12, Vol.127 (1407), p.61-74
1. Verfasser:	Gane, Edward John
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - epidemiology Causality Child Child, Preschool Combined Modality Therapy Comorbidity Complications Cost of Illness Diseases Drug Delivery Systems Female Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology Humans Infant Interferon-alpha - therapeutic use Liver Liver Cirrhosis - drug therapy Liver Cirrhosis - epidemiology Liver Neoplasms - drug therapy Liver Neoplasms - epidemiology Male Middle Aged New Zealand - epidemiology Prevalence Protease Inhibitors - therapeutic use Severity of Illness Index Treatment Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Describes the burden of hepatitis C virus (HCV) infection. Estimates the impact of increased treatment uptake and efficacy on the projected health burden from liver-related complications in New Zealanders with chronic HCV infection. Also estimates the impact of delaying any access to new therapies for 1 or 2 years. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.
ISSN:	0028-8446 1175-8716 1175-8716